Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.

Packer, Milton; Anker, Stefan D; Butler, Javed; Filippatos, Gerasimos; Ferreira, Joao Pedro; Pocock, Stuart J; Rocca, Hans-Peter Brunner-La; Janssens, Stefan; Tsutsui, Hiroyuki; Zhang, Jian; +7 more... Brueckmann, Martina; Jamal, Waheed; Cotton, Daniel; Iwata, Tomoko; Schnee, Janet; Zannad, Faiez; EMPEROR-Reduced Trial Committees and Investigators; (2021) Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European heart journal, 42 (6). pp. 671-680. ISSN 0195-668X DOI: https://doi.org/10.1093/eurheartj/ehaa968

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1093/eurheartj/ehaa968

Abstract

Item Type Article
Faculty and Department Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID 33459776
Elements ID 155517

Share

Download

Filename: ehaa968.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar